A traditional Chinese medicine composition for treating oral mucosal damage caused by antineoplastic drugs

Abstract

The invention provides a traditional Chinese medicine composition for treating oral mucosal damage caused by antineoplastic drugs, which comprises the following components in parts by weight: 9-15 parts by weight of Cimicifuga, 10-20 parts by weight of Baiji, 10-20 parts by weight of Flos Lonicerae Parts, wood butterfly 6-9 parts by weight, Scrophulariaceae 9-20 parts by weight, cicada slough 3-6 parts by weight, angelica 6-15 parts by weight, licorice 5-12 parts by weight. The invention can significantly improve and cure oral mucosal damage caused by antitumor drugs in a short period of time, is safe to use, has definite curative effect, and obviously improves the quality of life of patients without reducing the intensity of antitumor treatment.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating oral mucosal damage caused by antineoplastic drugs. Background technique [0002] With the rapid development of precision medicine today, oral mucosal injury is a common complication in cancer patients receiving antineoplastic drugs. In patients with solid tumors, about 40% of patients will develop severe oral mucosal damage after receiving conventional doses of antineoplastic drugs. For patients with hematological tumors, they must receive high-dose chemotherapy before hematopoietic stem cell transplantation, and about 90% of patients will suffer from oral mucosal damage. [0003] However, antineoplastic drug-related oral mucosal injury will bring a lot of pain to patients, mainly manifested as varying degrees of inflammatory changes, dryness, sensitivity, ulcers, etc. in the oral mucosa. ...

AI Technical Summary

Problems solved by technology

[0005] Although the above methods can slightly relieve oral mucosal injury, there is still a lack of sufficient clinical data to support the effectiveness of the treatment of oral mucosal injury, and no drugs have been approved for the treatment of radiation-induced oral mucositis at home and abroad, mostly based on expert consensus , some recommendations are still in the low-to-medium quality and weak recommendation research stage, and there is a lack of high-quality research

Our clinical experience also shows that the efficacy of the above methods is not ideal

What is even more worrying is that oral mucosal damage not only affects the patient's psychology and quality of life, but also has a higher risk of developing into systemic infection or even sepsis, which is life-threatening in severe cases

Such patients can only suspend the treatment because they cannot continue to tolerate the original dose of anti-tumor treatment

Even after the drug is stopped, the oral mucosal injury still takes half a month to one month or even several months to subside. When the patient recovers and receives reduction therapy again, the risk of severe oral mucosal injury is still high, and the dose reduction or even drug withdrawal is adopted. Undoubtedly, the measures weaken the treatment intensity, affect the progress of anti-tumor treatment, and threaten the long-term survival of patients.

[0006] In general, domestic and foreign treatment methods for oral mucosal injury caused by anti-tumor drugs have limited clinical efficacy and lack of high-level evidence support. Some studies did not consider the intensity of anti-tumor treatment and ignored the overall survival of patients.

Images